AMS 800 Artificial Urinary Sphincter (AUS)
Boston Scientific Corp · Decision date Feb 25, 2026
What did the FDA decide?
FDA records P000053/S141 as a supplement to PMA P000053, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 25, 2026.
FDA approval order statement
approval to add a new supplier for a cuff backing raw material
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Feb 25, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P000053/S141
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- EZY
- Decision code
- OK30
- Decision date
- Feb 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, incontinence, mechanical/hydraulic.
- Applicant
- Boston Scientific Corp
- Product code
- EZY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P000053. Subsequent supplements may change the device or its indications.
FDA decision timeline
P000053 · Original PMA
AMS SPHINCTER 800 URINARY CONTROL SYSTEM
P000053/S141 received
Application receipt date recorded by FDA.
P000053/S141 · FDA decision
30-Day Notice
P000053/S142 · Related supplement
AMS 800 Artificial Urinary Sphincter (AUS)
Timeline entries are records held by MedtechLedger for P000053. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000053
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA approval | Jun 14, 2001 | FDA | |
AMS 800 Artificial Urinary Sphincter (AUS)P000053/S142 | Boston Scientific Corp | PMA supplement | Sep 14, 2026 | FDA |
Explore the linked device profile
Other records with product code EZY
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ProACT Adjustable Continence Therapy for MenP130018/S006 | Uromedica, Inc. | PMA supplement | Feb 11, 2026 | FDA |
ProACT Adjustable Continence Therapy for MenP130018/S005 | Uromedica, Inc. | PMA supplement | Jan 28, 2026 | FDA |
ProACT Adjustable Continence Therapy for MenP130018/S004 | Uromedica, Inc. | PMA supplement | Oct 3, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 100 Boston Scientific Way, Marlboro, MA, 01752
Sources and methodology
- Original FDA record: P000053/S141
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



